Dr. Nancy Holekamp has been actively involved in clinical research, having served as principal investigator or sub-investigator for more than 15 national clinical trials dealing with age-related macular degeneration, retinal vascular occlusion, and diabetic retinopathy. Her efforts in research have resulted in more than 60 peer-reviewed publications and 15 book chapters, and numerous speaking invitations both nationally and internationally. Diabetes is at epidemic levels, and over 29 million people in the U.S. alone suffer from this disease.
What some of them don't do, however, is keep a check on their eyes.
All people with diabetes, both type-1 and type-2, are at risk for diabetic vision loss.
A recent report published in Med Scape showed how this demographic is prone to skipping their eye exams.
In the Spring of 2015, the FDA approved a first-of-its-kind implant called Iluvien that slowly releases medication for three years, eliminating the burden/expense of monthly visits, as well as the emotional impact of worrying when the vision loss will return.
What do you need to know about Iluvien?
Nancy Holecamp, MD, joins Melanie Cole, MS, to discuss diabetes blindness and this new medication that can reduce vision loss.
New Hope for Diabetes Blindness
Guest
: Nancy Holecamp, MD
From the Show: Health Radio
Summary: Between 40 to 45 percent of Americans diagnosed with diabetes have some stage of diabetic retinopathy.
Air Date: 9/21/15
Duration: 10
Host: Melanie Cole, MS
Tagged under